Wed, Jan 28, 2015, 4:28 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • b_leaguered b_leaguered Feb 15, 2014 8:38 AM Flag

    The Best Biotech Takeover Targets for 2014

    See thelifesciencesreportDOTcom

    "Large-cap pharmaceutical companies, instead of starting from scratch on a new patent, want an easier and more effective way to replace their lost "cash-cow" revenue. They will look to acquire biotech companies—and their phase 2 or phase 3 drugs."

    This could be the biggest year ever for investing in biotech takeover targets—all due to the patent cliff.

    Sanofi (NYSE ADR: SNY), Novartis AG (NYSE ADR: NVS), Roche Holding Ltd. (RHHBY), AstraZeneca PLC (NYSE ADR: AZN), and Eli Lilly & Co. (NYSE: LLY)will all be losing more than $6 billion each in annual revenue this year due to expiring patents.

    The ideal candidates are small-cap biotech firms whose pipelines include late-stage drug candidates or other promising pharmaceuticals.

    With that criteria in mind, here are six small-cap biotech firms on the list of takeover targets to watch in 2014. . .

    Biotech Takeover Targets in 2014
    (top of the list)

    Insmed Inc. (Nasdaq: INSM) primarily develops inhalation therapies for the treatment of lung diseases. Insmed's most notable project is ARIKACE, an inhaled antibiotic for patients suffering from cystic fibrosis and non-tuberculous mycobacteria. Currently, ARIKACE is in phase II trials in the United States and phase III trials in Canada and Europe.

    INSM stock has gained an impressive 241% in the last year and currently trades at $19.73. Insmed has a market cap of just $772 million, which also makes it an attractive takeover option for large-cap pharmaceutical companies.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
15.26-0.650(-4.09%)4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.